Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
14 Juin 2022 - 1:30PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a biotech company dedicated to fighting infectious
diseases including coronavirus, announces the publication of an
article co-authored by Oragenics and collaborators at Inspirevax
and the National Research Council of Canada (“NRC”) Human Health
Therapeutics Research Centre in Scientific Reports, a Nature
journal. The publication, available [https://rdcu.be/cPyZF] and
titled “Intranasal Immunization with a Proteosome-Adjuvanted
SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and
Efficacious in Mice & Hamsters,” concluded that Oragenics’
intranasal vaccine candidate, NT-CoV2-1, warrants further
development as a novel SARS-CoV-2 vaccine.
“We’re proud to have our innovative intranasal vaccine candidate
studies published in a reputable, peer-reviewed scientific journal,
and believe this heightened recognition underscores the need for
vaccines that address the limitations of currently available
options. These published data, and our on-going GLP toxicology
study will be part of our preclinical data package seeking
permission to enter our first-in human clinical trials,” said
Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.
The article, which was published as a preprint in bioRxiv in
March 2022, describes studies that evaluated a novel spike protein
subunit vaccine formulation, NT-CoV2-1, containing a
proteosome-based mucosal adjuvant designed for intranasal
immunization. The authors concluded that the intranasal formulation
induced robust antigen-specific IgG and IgA titers in the blood and
lungs of mice and was highly efficacious in a hamster challenge
model, reducing the viral load below the limit of detection. In
both mice and hamsters, the antibodies had strong neutralizing
activity, preventing the cellular binding of the viral spike
protein based on the ancestral reference strain and variants of
concern.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is NT-CoV2-1, an
intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the NIH and the NRC with a
focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. Its lantibiotics
program features a novel class of antibiotics against bacteria that
have developed resistance to commercial antibiotics. For more
information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of its vaccine candidate and lantibiotics candidate
under the timelines and in accord with the milestones it projects;
the Company’s ability to obtain funding, non-dilutive or otherwise,
for the development of the vaccine and lantibiotic product
candidates, whether through its own cash on hand, or another
alternative source; the regulatory application process, research
and development stages, and future clinical data and analysis
relating to vaccines and lantibiotics, including any meetings,
decisions by regulatory authorities, such as the FDA and
investigational review boards, whether favorable or unfavorable;
the potential application of our vaccine candidate to variants and
other coronaviruses; the Company’s ability to obtain, maintain and
enforce necessary patent and other intellectual property
protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments and demand for
vaccines and antibiotics; the Company’s expectations as to
administration, manufacturing, storage and distribution; other
potential adverse impacts due to the global COVID-19 pandemic, such
as delays in regulatory review, interruptions to manufacturers and
supply chains, adverse impacts on healthcare systems and disruption
of the global economy; and general economic and market conditions
and risks, as well as other uncertainties described in our filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220614005493/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900 msullivan@oragenics.com Or LHA Investor
Relations Tirth T. Patel 212-201-6614 tpatel@lhai.com
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024